Winnipeg Free Press - ONLINE EDITION

Cangene signs deal to bring Episil to American market

Cangene Corporation has entered into an agreement with a Swedish company, Camurus AB, for exclusive rights to commercialize Episil in the United States.

The drug is used for the management and relief of pain associated with oral lesions, including oral mucositis (OM), which results from cancer therapy and other causes.

Cangene plans to launch Episil in the U.S. in October 2012.

Headquartered in Winnipeg, Cangene’s products are sold worldwide and include products that have been accepted into the U.S. Strategic National Stockpile. It operates manufacturing facilities in Winnipeg and Baltimore and three U.S. and one Canadian plasma-collection facilities operating under the name Cangene Plasma Resources.

 

You can comment on most stories on winnipegfreepress.com. You can also agree or disagree with other comments. All you need to do is register and/or login and you can join the conversation and give your feedback.

Have Your Say

New to commenting? Check out our Frequently Asked Questions.

The Winnipeg Free Press does not necessarily endorse any of the views posted. By submitting your comment, you agree to our Terms and Conditions. These terms were revised effective April 16, 2010.

letters

Make text: Larger | Smaller

LATEST VIDEO

Winnipeg Jets Kane, Thorburn, Little and Trouba sum up the season

View more like this

Photo Store Gallery

  • PHIL HOSSACK / WINNIPEG FREE PRESS 070619 LIGHTNING ILLUMINATES AN ABANDONED GRAIN ELEVATOR IN THE VILLAGE OF SANFORD ABOUT 10PM TUESDAY NIGHT AS A LINE OF THUNDERSTORMS PASSED NEAR WINNIPEG JUST TO THE NORTH OF THIS  SITE.
  • A squirrel enjoys the morning sunshine next to the duck pond in Assiniboine Park Wednesday– June 27, 2012   (JOE BRYKSA / WINNIPEG FREE PRESS)

View More Gallery Photos

Poll

Do you miss the era of drive-in movie theatres?

View Results

View Related Story

Ads by Google